Phase 3 Trial Shows Positive Results for Oral Acne Drug Denifanstat
The once-daily FASN inhibitor met all primary and secondary endpoints for treating moderate to severe acne, with data to be presented at the EADV Congress.
The once-daily FASN inhibitor met all primary and secondary endpoints for treating moderate to severe acne, with data to be presented at the EADV Congress.
Concerns about skin flap viability have long kept many surgeons from combining these procedures. A new case series takes a closer look at whether that caution is still warranted.